Yu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yu Wang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Chak Kwong Cheng
Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China
1 shared publication - Chang Wang
Department of Nephrology, Institute of Nephrology, Second Affiliated Hospital of Hainan Medical University, Haikou, 570311, China, hainmc.edu.cn
1 shared publication - Chenqiu Ran
School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China
1 shared publication Chi-Wai Lau
1 shared publication- Hongyan Pan
Department of Endocrinology and Metabolism, Shenzhen University General Hospital and Shenzhen University Academy of Clinical Medical Sciences, Shenzhen University, Shenzhen, China
1 shared publication - Huaqiu He
Department of Endocrinology and Metabolism, Shenzhen University General Hospital and Shenzhen University Academy of Clinical Medical Sciences, Shenzhen University, Shenzhen, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , e6075025
Causal Association Between Commonly Used Medicines and Diabetes‐Related Eye Diseases: Univariable and Multivariable Mendelian Randomization Study
Background: Diabetic patients require long‐term polypharmacy, yet the causal effects of these medications on ocular complications—specifically diabetic retinopathy (DR), diabetic maculopathy (DMac), and glaucoma—remain unclear due to confounding in observational studies. Methods: We performed a Mendelian randomization (MR) study using GWAS summary statistics for 23 common medication classes and five diabetic eye diseases. Multivariable MR (MVMR) was employed to adjust for key comorbidities (e.g., hypertension, type 2 diabetes), while enrichment analyses explored biological mechanisms. Results: In the univariable MR (UVMR) analysis, drugs used in diabetes, agents acting on the renin–angiotensin system, and several other medication classes showed significant associations with increased risks of diabetic eye diseases. Crucially, MVMR confirmed robust causal links after adjusting for key comorbidities. Specifically, drugs used in diabetes remained associated with DMac (OR = 1.44, p = 1.31 × 10 −11 ), DR (OR = 1.23, p = 1.26 × 10 −8 ), neovascular glaucoma (OR = 1.19, p = 0.003), and senile cataract (OR = 1.10, p = 9.25 × 10 −12 ) independent of type 2 diabetes liability. Similarly, thyroid preparations retained significance for DMac (OR = 1.26, p = 4.35 × 10 −10 ), DR (OR = 1.17, p = 9.53 × 10 −10 ), and senile cataract (OR = 1.04, p = 0.004) after adjusting for hypothyroidism. Additionally, adrenergic inhalants were independently linked to senile cataract (OR = 1.07, p = 0.008) after adjusting for asthma. Pathway analysis highlighted hormone transport and MAPK signaling as potential mechanisms. Conclusion: Our findings provide genetic evidence supporting potential comorbidity‐independent causal links between specific systemic medications—particularly diabetes and thyroid drugs—and ocular complications, suggesting the importance of ophthalmological monitoring in these patients.
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , e6075025
Open AccessCausal Association Between Commonly Used Medicines and Diabetes‐Related Eye Diseases: Univariable and Multivariable Mendelian Randomization Study
Background: Diabetic patients require long‐term polypharmacy, yet the causal effects of these medications on ocular complications—specifically diabetic retinopathy (DR), diabetic maculopathy (DMac), and glaucoma—remain unclear due to confounding in observational studies. Methods: We performed a Mendelian randomization (MR) study using GWAS summary statistics for 23 common medication classes and five diabetic eye diseases. Multivariable MR (MVMR) was employed to adjust for key comorbidities (e.g., hypertension, type 2 diabetes), while enrichment analyses explored biological mechanisms. Results: In the univariable MR (UVMR) analysis, drugs used in diabetes, agents acting on the renin–angiotensin system, and several other medication classes showed significant associations with increased risks of diabetic eye diseases. Crucially, MVMR confirmed robust causal links after adjusting for key comorbidities. Specifically, drugs used in diabetes remained associated with DMac (OR = 1.44, p = 1.31 × 10 −11 ), DR (OR = 1.23, p = 1.26 × 10 −8 ), neovascular glaucoma (OR = 1.19, p = 0.003), and senile cataract (OR = 1.10, p = 9.25 × 10 −12 ) independent of type 2 diabetes liability. Similarly, thyroid preparations retained significance for DMac (OR = 1.26, p = 4.35 × 10 −10 ), DR (OR = 1.17, p = 9.53 × 10 −10 ), and senile cataract (OR = 1.04, p = 0.004) after adjusting for hypothyroidism. Additionally, adrenergic inhalants were independently linked to senile cataract (OR = 1.07, p = 0.008) after adjusting for asthma. Pathway analysis highlighted hormone transport and MAPK signaling as potential mechanisms. Conclusion: Our findings provide genetic evidence supporting potential comorbidity‐independent causal links between specific systemic medications—particularly diabetes and thyroid drugs—and ocular complications, suggesting the importance of ophthalmological monitoring in these patients.
- 26 October 2023
- Published by Springer Nature in Journal of Physiology and Biochemistry
- Vol. 80 (1) , 113-126
High fat diet-induced downregulation of TRPV2 mediates hepatic steatosis via p21 signalling
The global prevalence and incidence of non-alcoholic fatty liver disease (NAFLD) are exhibiting an increasing trend. NAFLD is characterized by a significant accumulation of lipids, though its underlying mechanism is still unknown. Here we report that high-fat diet (HFD) feeding induced hepatic steatosis in mice, which was accompanied by a reduction in the expression and function of hepatic TRPV2. Moreover, conditional knockout of TRPV2 in hepatocytes exacerbated HFD-induced hepatic steatosis. In an in vitro model of NAFLD, TRPV2 regulated lipid accumulation in HepG2 cells, and TRPV2 activation inhibited the expression of the cellular senescence markers p21 and p16, all of which were mediated by AMPK phosphorylation. Finally, we found that administration of probenecid, a TRPV2 agonist, impaired HFD-induced hepatic steatosis and suppressed HFD-induced elevation in p21 and p16. Collectively, our findings imply that hepatic TRPV2 protects against the accumulation of lipids by modulating p21 signalling.
- 26 October 2023
- Published by Springer Nature in Journal of Physiology and Biochemistry
- Vol. 80 (1) , 113-126
High fat diet-induced downregulation of TRPV2 mediates hepatic steatosis via p21 signalling
The global prevalence and incidence of non-alcoholic fatty liver disease (NAFLD) are exhibiting an increasing trend. NAFLD is characterized by a significant accumulation of lipids, though its underlying mechanism is still unknown. Here we report that high-fat diet (HFD) feeding induced hepatic steatosis in mice, which was accompanied by a reduction in the expression and function of hepatic TRPV2. Moreover, conditional knockout of TRPV2 in hepatocytes exacerbated HFD-induced hepatic steatosis. In an in vitro model of NAFLD, TRPV2 regulated lipid accumulation in HepG2 cells, and TRPV2 activation inhibited the expression of the cellular senescence markers p21 and p16, all of which were mediated by AMPK phosphorylation. Finally, we found that administration of probenecid, a TRPV2 agonist, impaired HFD-induced hepatic steatosis and suppressed HFD-induced elevation in p21 and p16. Collectively, our findings imply that hepatic TRPV2 protects against the accumulation of lipids by modulating p21 signalling.
- 1 July 2021
- Published by Elsevier in Chinese Chemical Letters
- Vol. 32 (7) , 2197-2202
Integrated metabolomics analysis of the effect of PPARδ agonist GW501516 on catabolism of BCAAs and carboxylic acids in diabetic mice
- 1 July 2021
- Published by Elsevier in Chinese Chemical Letters
- Vol. 32 (7) , 2197-2202
Integrated metabolomics analysis of the effect of PPARδ agonist GW501516 on catabolism of BCAAs and carboxylic acids in diabetic mice